This is a single-institution, prospective, phase I dose escalation trial of lonsurf combined with gemcitabine and nab-paclitaxel using the 3+3 design. This study will enroll 18 patients over 12-15 months.~Primary Objective To determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel~Secondary Objectives~Examine safety and toxicity of the combination~Estimate response rate to the combination~Estimate median overall survival (mOS) of the treated population~Estimate median progression free survival (mPFS) of the treated population~Estimate disease control rate (DCR) at 8 weeks~Evaluate quality of life while receiving the combination therapy
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)